Sight Sciences (SGHT) Expected to Announce Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Sight Sciences to post earnings of ($0.29) per share and revenue of $16.51 million for the quarter. Sight Sciences has set its FY 2025 guidance at EPS.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same quarter in the prior year, the business earned ($0.22) EPS. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Trading Down 2.1 %

NASDAQ:SGHT traded down $0.07 on Friday, hitting $3.22. 144,323 shares of the stock were exchanged, compared to its average volume of 210,432. The stock has a market capitalization of $165.29 million, a price-to-earnings ratio of -3.16 and a beta of 2.46. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences has a 52 week low of $2.03 and a 52 week high of $8.45. The company's 50-day moving average price is $2.60 and its 200 day moving average price is $3.42.

Wall Street Analyst Weigh In

A number of research firms have commented on SGHT. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Stifel Nicolaus decreased their price objective on Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. UBS Group cut their target price on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Piper Sandler decreased their target price on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Finally, Lake Street Capital cut their price target on shares of Sight Sciences from $3.00 to $2.50 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $3.83.

Insider Buying and Selling at Sight Sciences

In other Sight Sciences news, EVP Manohar K. Raheja acquired 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the transaction, the executive vice president now owns 145,000 shares of the company's stock, valued at $395,850. This trade represents a 7.41 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Badawi sold 24,174 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total value of $55,600.20. Following the sale, the chief executive officer now directly owns 6,010,580 shares of the company's stock, valued at approximately $13,824,334. The trade was a 0.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,196 shares of company stock valued at $81,001. Company insiders own 28.90% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.